Abstract:Achieving high-efficiency tumor targeting after systemic delivery is a considerable challenge facing oncolytic gene therapists. Efficient retargeting should be combined with efforts to improve in vivo safety, reduce hepatotoxicity, minimize off-target interactions, and improve antitumoral potency and efficacy. We previously described the successful retargeting of adenovirus serotype 5 (Ad5) to α(v)β(6), an integrin that is highly overexpressed in numerous human carcinomas. In this study, we have further modified this construct by introducing mutations that ablate coxsackievirus-adenovirus receptor (CAR) binding and putative interactions with factor IX (FIX)/C4b-binding protein (C4BP). We have found that the resulting vector, Ad5-477dlTAYT(A20), displays a desirable in vivo safety profile. This vector does not agglutinate human erythrocytes, fails to cause thrombocytopenia after intravenous delivery, has limited induction of proinflammatory cytokines, and results in low-level toxicity (aspartate aminotransferase/alanine aminotransferase) when compared with Ad5-EGFP(WT). Furthermore, it has reduced accumulation in Kupffer cells (1 hr) and limited hepatocyte transduction at later time points (24 and 96 hr). The parental vector, Ad5-EGFP(A20), also displayed many of these desirable properties. As a result of the improved safety profile of both A20-modified vectors, we escalated the dose from 2×10(10) to 4×10(10) viral particles in an antitumoral efficacy study. We observed improvements in reducing percent tumor growth at early time points (96 hr) when compared with Ad5-EGFP(WT), although increasing the dose did not affect the therapeutic outcome beneficially. On completion of the experiment, we detected increased E1A staining in the tumors of all A20-treated groups and we determined that E1A expression was localized largely within α(v)β(6)(+) tumor cells. However, in spite of apparently efficient tumor transduction, this did not result in enhanced antitumoral efficacy as the virus failed to disseminate effectively throughout the tumor mass, presumably due to physical intratumoral restrictions. This highlights a remaining challenge that needs to be overcome before such vectors can be developed for future cancer gene therapy applications.

Assessment of a Capsid-Modified E1B 55-Kda Protein-Deficient Adenovirus Vector for Tumor Treatment

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Oncolytic adenovirus H101 enhanced antitumor effects of PD-1 blockade by downregulating CD47 on tumor cells

Intra-tumor Injection of H101, a Recombinant Adenovirus, in Combination with Chemotherapy in Patients with Advanced Cancers: a Pilot Phase II Clinical Trial.

[Phase II Clinical Study of Intratumoral H101, an E1B Deleted Adenovirus, in Combination with Chemotherapy in Patients with Cancer].

Potent Antitumor Efficacy Of An E1b 55kda-Deficient Adenovirus Carrying Murine Endostatin In Hepatocellular Carcinoma

Arg-Gly-Asp (Rgd)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells in Vitro and in Mice

The antitumor effects of oncolytic adenovirus H101 against lung cancer

[Safety of an E1B Deleted Adenovirus Administered Intratumorally to Patients with Cancer].

RESEARCH ON DISSEMINATION OF RECOMBINANT ADENOVIRUS INTRA-TUMOR INJECTION IN HUMAN BODY

Inhibition of Retinoblastoma in Vitro and in Vivo with Conditionally Replicating Oncolytic Adenovirus H101

A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy

[Effect of Expression of Coxsackie and Adenovirus Receptor on Antitumor Activity of Genetically Modified Adenovirus].

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5

Significant Antitumor Activity Of Oncolytic Adenovirus Expressing Human Interferon-Beta For Hepatocellular Carcinoma

538. Fiber Chimeric Oncolytic Adenoviral Vectors Mediate Efficient Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells in Vitro and in Vivo

Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy

A Novel Oncolytic Adenovirus Expressing Escherichia Coli Cytosine Deaminase Exhibits Potent Antitumor Effect on Human Solid Tumors

A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy.

Increased Safety With Preserved Antitumoral Efficacy On Hepatocellular Carcinoma With Dual-Regulated Oncolytic Adenovirus